Although we have taken a more conservative stance on development timelines, we continue to believe that Midatech’s technology platforms have significant commercial potential. We currently expect Midatech to sell both of its lead programmes (MTD201 and MTX110) direct in the US. Alternatively, either programme could represent an exciting licensing opportunity following the completion of pivotal trials in 2019e and 2020e respectively. We reiterate our long-term Buy recommendation with a revised tar ....
24 May 2018
Exciting newsflow highlights longer-term potential
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Exciting newsflow highlights longer-term potential
- Published:
24 May 2018 -
Author:
Dr Jens Lindqvist -
Pages:
3
Although we have taken a more conservative stance on development timelines, we continue to believe that Midatech’s technology platforms have significant commercial potential. We currently expect Midatech to sell both of its lead programmes (MTD201 and MTX110) direct in the US. Alternatively, either programme could represent an exciting licensing opportunity following the completion of pivotal trials in 2019e and 2020e respectively. We reiterate our long-term Buy recommendation with a revised tar ....